Preliminary results encouraging for EVOQUE tricuspid valve replacement

In patients with significant tricuspid regurgitation (TR) who received a new tricuspid valve replacement system, results at 30 days showed a reduction of TR and improvement of symptoms in the TRISCEND study. At 30 days, most patients (77.4%) had experienced no major adverse events. The device was deemed technically feasible, with an acceptable safety profile [1]. The TRISCEND study (NCT04221490) was an early feasibility study to assess the performance and safety of the Edwards’ EVOQUE tricuspid valve replacement system. This prospective, single-arm, multicentre study enrolled 56 patients with symptomatic moderate or greater TR to receive the EVOQUE valve replacement. At 30 days, 47 participants were available for follow-up. The participants were quite elderly (mean age 79 years) and had severe TR symptomatic (92% graded as severe or greater). A...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 9 July, 202129 July, 2021